Literature DB >> 25287942

Medical Marijuana programs: implications for cannabis control policy--observations from Canada.

Benedikt Fischer1, Sharan Kuganesan2, Robin Room3.   

Abstract

While prohibition has been the dominant regime of cannabis control in most countries for decades, an increasing number of countries have been implementing cannabis control reforms recently, including decriminalization or even legalization frameworks. Canada has held out from this trend, although it has among the highest cannabis use rates in the world. Cannabis use is universally criminalized, and the current (conservative) federal government has vowed not to implement any softening reforms to cannabis control. As a result of several higher court decisions, the then federal government was forced to implement a 'medical marijuana access regulations' program in 2001 to allow severely ill patients therapeutic use and access to therapeutic cannabis while shielding them from prosecution. The program's regulations and approval processes were complex and subject to extensive criticism; initial uptake was low and most medical marijuana users continued their use and supply outside the program's auspices. This year, the government introduced new 'marijuana for medical purposes regulations', which allow physicians to 'authorize' medical marijuana use for virtually any health condition for which this is considered beneficial; supply is facilitated by licensed commercial producers. It is expected that some 500,000 users, and dozens of commercial producers will soon be approved under the program, arguably constituting - as with medical marijuana schemes elsewhere, e.g. in California--de facto 'legalization'. We discuss the question whether the evolving scope and realities of 'medical cannabis' provisions in Canada offer a 'sneaky side door' or a 'better third way' to cannabis control reform, and what the potential wider implications are of these developments.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  Canada; Cannabis control; Medical marijuana; Medicalization; Policy

Mesh:

Substances:

Year:  2014        PMID: 25287942     DOI: 10.1016/j.drugpo.2014.09.007

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  20 in total

1.  Characteristics of Canadians likely to try or increase cannabis use following legalization for nonmedical purposes: a cross-sectional study.

Authors:  Harman S Sandhu; Laura N Anderson; Jason W Busse
Journal:  CMAJ Open       Date:  2019-06-14

Review 2.  Medical cannabis for chronic pain: can it make a difference in pain management?

Authors:  Mari Kannan Maharajan; Yu Jing Yong; Hong Yang Yip; Sze Shee Woon; Kar Mon Yeap; Khai Yeng Yap; Shuen Chi Yip; Kai Xian Yap
Journal:  J Anesth       Date:  2019-09-18       Impact factor: 2.078

Review 3.  Medical Marijuana and Marijuana Legalization.

Authors:  Rosalie Liccardo Pacula; Rosanna Smart
Journal:  Annu Rev Clin Psychol       Date:  2017-05-08       Impact factor: 18.561

4.  Natural Cannabinoids as Templates for Sleep Disturbances Treatments.

Authors:  Eric Murillo-Rodríguez; Sérgio Machado; Claudio Imperatori; Tetsuya Yamamoto; Henning Budde
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Medical marijuana laws and adolescent marijuana use in the USA from 1991 to 2014: results from annual, repeated cross-sectional surveys.

Authors:  Deborah S Hasin; Melanie Wall; Katherine M Keyes; Magdalena Cerdá; John Schulenberg; Patrick M O'Malley; Sandro Galea; Rosalie Pacula; Tianshu Feng
Journal:  Lancet Psychiatry       Date:  2015-06-15       Impact factor: 27.083

6.  Medical Marijuana Laws and Marijuana Use Among U.S. Adolescents: Evidence From Michigan Youth Risk Behavior Surveillance Data.

Authors:  Xinguang Chen; Bin Yu; Bonita Stanton; Robert L Cook; Ding-Geng Din Chen; Chukwuemeka Okafor
Journal:  J Drug Educ       Date:  2018-10-09

7.  Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013.

Authors:  Deborah S Hasin; Tulshi D Saha; Bradley T Kerridge; Risë B Goldstein; S Patricia Chou; Haitao Zhang; Jeesun Jung; Roger P Pickering; W June Ruan; Sharon M Smith; Boji Huang; Bridget F Grant
Journal:  JAMA Psychiatry       Date:  2015-12       Impact factor: 21.596

Review 8.  A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms.

Authors:  Maira Aguiar Werneck; Guilherme Trevizan Kortas; Arthur Guerra de Andrade; João Mauricio Castaldelli-Maia
Journal:  CNS Drugs       Date:  2018-12       Impact factor: 5.749

9.  Exploring the use of cannabis as a substitute for prescription drugs in a convenience sample.

Authors:  Sinikka L Kvamme; Michael M Pedersen; Kristine Rømer Thomsen; Birgitte Thylstrup
Journal:  Harm Reduct J       Date:  2021-07-10

10.  An Exploration of Self-Reported Medicinal Cannabis Use Among a Sample of Eastern Canadian Postsecondary Students.

Authors:  Jacqueline Smith; Jennifer Smith; Joel Mader; Gabrielle Guestier; Lauren Conn; Joy Maddigan
Journal:  J Behav Health Serv Res       Date:  2021-07-08       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.